oa Monitoring the treatment of myocardial stunning syndrome after acute carbon monoxide poisoning using arterial pulse wave analysis: a case report

References

1. Ernst A, Zibrak JD. Carbon monoxide poisoning. N Engl J Med. 1998; 26;339:22:1603–1608.
   [Google Scholar]
2. Weaver LK. Clinical practice. Carbon monoxide poisoning. N Engl J Med. 2009; 19;360:12:1217–1225.
   [Google Scholar]
3. Hampson NB, Piantadosi CA, Thom SR, Weaver LK. Practice recommendations in the diagnosis, management, and prevention of carbon monoxide poisoning. Am J Respir Crit Care Med. 2012; 1;186:11:1095–1101.
   [Google Scholar]
4. Satran D, Henry CR, Adkinson C, Nicholson CI, Bracha Y, Henry TD. Cardiovascular manifestations of moderate to severe carbon monoxide poisoning. J Am Coll Cardiol. 2005; 3;45:9:1513–1516.
   [Google Scholar]
5. Fotbolcu H, Incedere O, Bakal RB, Tanalp AC, Astarcioglu MA, Dindar I. Reversible myocardial stunning due to carbon monoxide exposure. Cardiovasc J Afr. 2011; 22:2:93–95.
   [Google Scholar]
6. Tritapepe L, Macchiarelli G, Rocco M, Scopinaro F, Schillaci O, Martuscelli E, Motta PM. Functional and ultrastructural evidence of myocardial stunning after acute carbon monoxide poisoning. Crit Care Med. 1998; 26:4:797–801.
   [Google Scholar]
7. Hampson NB, Zmaeff JL. Outcome of patients experiencing cardiac arrest with carbon monoxide poisoning treated with hyperbaric oxygen. Ann Emerg Med. 2001; 38:1:36–41.
   [Google Scholar]
8. Henry CR, Satran D, Lindgren B, Adkinson C, Nicholson CI, Henry TD. Myocardial injury and long-term mortality following moderate to severe carbon monoxide poisoning. JAMA. 2006; 25;295:4:398–402.
   [Google Scholar]
9. Ng TM, Akhter MW. Levosimendan: dual mechanisms for acute heart failure…and beyond? Minerva Cardioangiol. 2005; 53:6:565–584.
   [Google Scholar]
10. García González MJ, Domínguez Rodríguez A. Pharmacologic treatment of heart failure due to ventricular dysfunction by myocardial stunning: potential role of levosimendan. Am J Cardiovasc Drugs. 2006; 6:2:69–75.
    [Google Scholar]
11. Kasikcioglu HA, Cam N. A review of levosimendan in the treatment of heart failure. Vasc Health Risk Manag. 2006; 2:4:389–400.
    [Google Scholar]
12. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002; 20;360:9328:196–202.
    [Google Scholar]
13. Hadian M, Kim HK, Severyn DA, Pinsky MR. Cross-comparison of cardiac output trending accuracy of LiDCO, PiCCO, FloTrac and pulmonary artery catheters. Crit Care. 2010; 14:6:R212.
    [Google Scholar]
14. Marik PE, Cavallazzi R, Vasu T, Hirani A. Dynamic changes in arterial waveform derived variables and fluid responsiveness in mechanically ventilated patients: a systematic review of the literature. Crit Care Med. 2009; 37:9:2642–2647.
    [Google Scholar]
15. Montenij LJ, de Waal EE, Buhre WF. Arterial waveform analysis in anesthesia and critical care. Curr Opin Anaesthesiol. 2011; 24:6:651–656.
    [Google Scholar]
16. Kao LW, Nañagas KA. Carbon monoxide poisoning. Emerg Med Clin North Am. 2004; 22:4:985–1018.
    [Google Scholar]
17. Bolli R, Marbán E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev. 1999; 79:2:609–634.
    [Google Scholar]
18. Rocco M, Carbone I, Morelli A, Palantonio P, Rossi S, Spadetta G, Passariello R, Pietropaoli P. The calcium sensitizer levosimendan improves carbon monoxide poisoning related stunned myocardium: a cardiac magnetic resonance study. Acta Anaesthesiol Scand. 2006; 50:7:897–898.
    [Google Scholar]